Please assess the completion status of the following clinical trial:

Trial Title: A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be adults ranging in age from 21-55 years old.~* Be dependent on opioids.~* Be willing to accept or desiring of opioid detoxification.~* He healthy as determined by medical screen, history, and vitals.~* Be without significant psychiatric illness besides drug dependence.~* Be without chronic pain.~* Fluent in English (speaking, writing, and reading).~* Be willing and able to participate.~Exclusion Criteria:~* Previous documented allergy to buprenorphine or morphine.~* Are dependent on other drugs besides opioids and tobacco.~* Have current history of significant use of alcohol or sedative/hypnotics.~* Have evidence of significant medical (e.g., insulin dependent diabetes mellitus) or psychiatric (e.g., schizophrenia) illness.~* Are pregnant (female volunteers will receive a pregnancy test before participation in the study and routinely during the study).~* Have an abnormal or prolongation of the corrected QT interval (QTc) on a baseline electrocardiogram (ECG).~* Are seeking treatment for their substance dependence.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Morphine, then Buprenorphine (Type: EXPERIMENTAL): Healthy, out of treatment opioid-dependent residential volunteers (N=7) were randomized to receive morphine (120 mg/day i.m.) administered in four divided doses each day for 9 days (30 mg of morphine four times per day). Participants then underwent an 18-day period of spontaneous opioid withdrawal, during which four double blind i.m. placebo injections were administered daily. After the period of spontaneous withdrawal, participants received buprenorphine (32 mg/day i.m.) administered in four divided doses each day for 9 days (8 mg of buprenorphine four times per day) followed by a second 18-day period of spontaneous withdrawal identical to the withdrawal period described above.
- Buprenorphine, then Morphine (Type: EXPERIMENTAL): Healthy, out of treatment opioid-dependent residential volunteers (N=7) were randomized to receive buprenorphine (32 mg/day i.m.) administered in four divided doses each day for 9 days (8 mg of buprenorphine four times per day). Participants then underwent an 18-day period of spontaneous withdrawal, during which four double blind i.m. placebo injections were administered daily. After the period of spontaneous withdrawal, participants received morphine (120 mg/day i.m.) administered in four divided doses each day for 9 days (30 mg of morphine four times per day) followed by a second 18-day period of spontaneous withdrawal identical to the withdrawal period described above.

Based on this trial design, predict the completion outcome and termination type (if applicable).